Skip to main content

Advertisement

Table 1 Meta-analyses references of the studies on candidate IHC markers for survival in ESCC

From: Immunohistochemical prognostic markers of esophageal squamous cell carcinoma: a systematic review

Marker References Publication period of involved studies Number of eligible studies Number of patients Pooled HR 95% CI
EGFR Yu et al. [27] Until Nov, 2010 5 462 1.60 1.05–2.43
Wang et al. [28] Until Dec, 2013 13 1150 1.768 1.039–3.007
Cyclin D1 Zhao et al. [40] Until Apr, 2010 10 1376 1.78 1.49–2.12
Chen et al. [41] Until Apr, 2012 12 1295 1.82 1.50–2.20
P21 Chen et al. [41] Until Apr, 2012 7 683 1.28 0.70–2.33
P27 Chen et al. [41] Until Apr, 2012 6 478 0.51 0.26–1.00
P53 Chen et al. [41] Until Apr, 2012 20 2063 1.25 1.03–1.51
Survivin Chen et al. [41] Until Apr, 2012 4 295 1.57 0.91–2.69
Li et al. [58] Until Mar, 2012 3 (nuclei) 277 1.89 1.45–2.96
2 (cytoplasm) 113 0.96 0.16–5.69
Xia et al. [59] Until Nov, 2014 8 573 1.82 1.43–2.30
VEGF Chen et al. [41] Until Apr, 2012 16 1329 1.84 1.45–2.33
Chen et al. [71] Until Dec, 2011 26 2043 1.81 1.57–2.10
HIF-1α Ping et al. [74] Until Sep, 2013 12 942 1.78 1.41–2.24
Sun et al. [75] Until Dec, 2011 16 1261 0.32 0.115–0.887
E-cadherin Chen et al. [41] Until Apr, 2012 7 977 0.81 0.64–1.01
Xu et al. [78] Until Jun, 2012 9 1129 0.72 0.64–0.83
MTA1 Luo et al. [94] Until Oct, 2013 4 465 1.86 1.44–2.39
PD-L1 Qu et al. [97] Until Jul, 2016 7 1350 1.65 0.95–2.85
COX-2 Chen et al. [41] Until Apr, 2012 4 234 0.96 0.39–2.41
Li et al. [102] Until Dec, 2008 12 1167 1.42 1.07–1.90
OCT4 Nagaraja et al. [103] Until May, 2013 4 539 2.900 1.843–4.565
  1. IHC immunohistochemistry, ESCC esophageal squamous cell carcinoma, EGFR epidermal growth factor receptor, VEGF vascular endothelial growth factor, HIF-1α hypoxia-inducible factor-1α, MTA1 metastasis-associated protein 1, PD-L1 programmed cell death-ligand 1, COX-2 cyclooxygenase-2, OCT4 octamer-binding transcription factor 4, HR hazard ratio, CI confidence interval